Advanced Therapies 2021 | The evolving landscape of autologous and allogeneic therapies

Matthew Durdy, CEO, Cell and Gene Therapy Catapult, London, UK, talks on the evolving landscapes of autologous and allogeneic therapies. Autologous therapies are highly personalized and are able to overcome problems associated with immunogenicity, thus offering the potential for highly effective therapeutics. There is a, however, a growing interest in the development of allogeneic approaches that can be manufactured at a larger scale, although challenges around immunotolerance still need to be addressed. This interview took place at the Advanced Therapies Congress & Expo 2021.